Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Anchor Investment Management LLC

Anchor Investment Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1,024.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,249 shares of the biopharmaceutical company’s stock after acquiring an additional 2,049 shares during the period. Anchor Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,026,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Root Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $27,000. Ameriflex Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $32,000. ORG Partners LLC grew its stake in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $36,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the transaction, the executive vice president directly owned 64,273 shares in the company, valued at approximately $21,059,048.45. This trade represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 6,799 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the sale, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 53,923 shares of company stock worth $18,072,087. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $313.41 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a market cap of $41.56 billion, a P/E ratio of 183.28 and a beta of 0.36. The stock has a 50 day moving average of $344.35 and a 200-day moving average of $409.44.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the company earned ($0.65) earnings per share. The company’s revenue was up 84.9% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on ALNY. Barclays initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target on the stock. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.